Back to search

Article

Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical Setting

2025-06-25

Abstract excerpt

<h4>Background: </h4> /Objectives: Advances in understanding immune checkpoint pathways and tumor immune biology have enabled the development of immune checkpoint inhibitors (ICIs), particularly targeting the PD-1/PD-L1 axis, which has transformed cancer immu-notherapy. Despite their success across multiple tumor types, including melanoma, non-small-cell lung cancer, and gastrointestinal malignancies, variability...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f46f60d0-592d-53d6-8493-7fc7320f639a
DOI
10.20944/preprints202506.2039.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical SettingDOI 10.20944/preprints202506.2039.v1
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity
Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersSemantic proximity
Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity
Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.Semantic proximity
Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint InhibitorsSemantic proximity
Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity
Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity
The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity
Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitorsSemantic proximity
A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity
Select a neighboring publication to make it the new centre.